Details for Patent: 3,705,172

Summary for Patent: 3,705,172

Title:	N-trityl-imidazoles
Abstract:	N-TRITYL-IMIDAZOLES AND SALTS THEREOF OF THE FORMULA: 1-(((X)N-PHENYL)-C(-PHENYLENE-(X'')N'')(-PHENYLENE-(X")N") -),2-R,4-R1,5-R2-IMIDAZOLE WHEREIN R, R1 AND R2 ARE HYDROGEN, LOWER ALKYL OR PHENYL OR R1 AND R2 TOGETHER FORM AN ANELLATED BENZENE RING, X,X'' AND X" ARE ALKYL OF 1 TO 12 CARBON ATOMS OR AN ELECTRO-NEGATIVE MOIETY, AND N, N'' AND N" ARE AN INTEGER FROM 0 TO 2, OR PHARMACEUTICALLY ACCEPTABLE ACID SALTS THEREOF MAY BE PRODUCED BY REACTING A SILVER SALT OR ALKALI METAL SALT OF AN IMIDAZOLE OF THE FORMULA: 2-R,4-R1,5-R2-2-IMIDAZOLINE WITH A TRITYL HALIDE OF THE FORMULA: (X)N,(((X'')N''-PHENYL)-C(-PHENYLENE-(X")N")(-HAL)-)BENZENE WHEREIN THE SUBSTITUENTS ARE AS DEFINED AND HAL IS HALOGEN. THESE COMPOUNDS ARE USEFUL AS ANTIMYCOTICS.
Inventor(s):	Karl-Heinz Buchel, Erik K Regel, Manfred Plempel
Assignee:	Bayer AG
Application Number:	US13797A
Patent Claim Types: see list of patent claims

United States Patent 3,705,172: Scope, Claim Coverage, and US Landscape

What does US Patent 3,705,172 claim?

No claim text was provided in the prompt (“The claims are: ” is incomplete). Without the actual claim language, a claim-by-claim scope and patentability/validity analysis cannot be produced accurately.

What is the patent landscape around US 3,705,172 (US-only)?

No bibliographic fields (assignee, title, filing date, priority, IPC/CPC, or cited references) were provided in the prompt. Without those identifiers, the US landscape cannot be built reliably.

What does “scope” mean for this patent in business terms?

Scope analysis requires at minimum: independent claim elements (for boundary-setting), claim dependencies (for fall-back coverage), and the inventor/assignee and priority chain (to locate overlapping prior art and later family members). Those inputs are missing.

Which competitors and follow-on filings are likely implicated?

A competitor and follow-on mapping is driven by:

• exact active ingredient(s),
• dosage form(s),
• claimed process steps (if process patent),
• method-of-treatment language (if medical use),
• and pharmacological class.

None of those inputs are available from the provided content.

---

Key Takeaways

• A complete and accurate scope and claims analysis for US Drug Patent 3,705,172 cannot be generated because the claim text and core bibliographic identifiers were not supplied.
• A defensible patent landscape cannot be constructed because overlapping patents require exact title/assignee/priority and cited-reference data.

---

FAQs

1. Can the claim scope be analyzed without the claim language?
   No. Scope depends on the exact wording of each claim element and dependency structure.

2. Can the US patent landscape be mapped without bibliographic identifiers?
   No. Landscape mapping requires title/assignee/priority (or equivalent identifiers) to locate relevant US families and citing documents.

3. What inputs are required for an infringement-relevant scope read?
   Independent and dependent claim text, plus the patent’s bibliographic metadata.

4. What inputs are required for a prior-art and obviousness landscape?
   Priority dates, cited references, and the claim feature breakdown.

5. Can this be done from only the patent number (3,705,172)?
   Not under the provided constraints, because the prompt did not include the necessary patent text or identifiers to proceed.

---

References

No sources were provided or cited.

Drugs Protected by US Patent 3,705,172

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 3,705,172

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	278001
Austria	285600
Belgium	720801
Belgium	721378
Brazil	6802293
Canada	938611
Canada	946391